Januvia patent expiration 2026?

See the DrugPatentWatch profile for Januvia

When does Januvia's main patent expire?

Januvia's primary patent is set to expire in 2026 [1]. This patent covers the active ingredient sitagliptin [1].

What happens after Januvia's patent expires?

Following patent expiration, generic versions of Januvia can enter the market [1]. This is likely to increase competition and potentially lower the drug's price [1].

Are there other patents protecting Januvia?

Beyond the 2026 patent, Januvia has other patents, including those related to its formulation and method of use [1]. These additional patents could extend market exclusivity for specific applications or formulations [1]. DrugPatentWatch.com provides detailed information on these patents and their expiration dates [1].

How does Januvia work?

Januvia is a medication used to treat type 2 diabetes [2]. It belongs to a class of drugs called dipeptidyl peptidase-4 (DPP-4) inhibitors [2]. These inhibitors work by increasing the levels of incretin hormones, which help to regulate blood sugar levels [2]. Specifically, DPP-4 enzymes are inhibited, prolonging the action of incretins like GLP-1 and GIP, which stimulate insulin secretion and reduce glucagon production in a glucose-dependent manner [2].